As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of INmune Bio Inc. The largest reported stake is Highbridge Capital Management, LLC's, at 5.2%. 4 filings are on record since July 2, 2025 (Schedule 13G/A, August 14, 2025).
Sell to companies like INmune Bio Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Highbridge Capital Management, LLC · Sole voting: 1,454,400 · Shared voting: 0 · Sole dispositive: 1,454,400 · Shared dispositive: 0 · SCHEDULE 13G/A, 2025-08-14
- · Reporting person: CVI Investments, Inc. · Sole voting: 0 · Shared voting: 1,396,279 · Sole dispositive: 0 · Shared dispositive: 1,396,279 · SCHEDULE 13G/A, 2025-08-14
- · Reporting person: Praetorian PR LLC · Sole voting: 0 · Shared voting: 771,200 · Sole dispositive: 0 · Shared dispositive: 771,200 · SCHEDULE 13G/A, 2025-08-14
- · Holder: CVI Investments, Inc. · Percent: 5.5% · SCHEDULE 13G
INmune Bio Inc. has 4 Schedule 13D or 13G filings on record since 2025-07-02. 1 holder's latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Highbridge Capital Management, LLC | 5.2% | 1,454,400 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| CVI Investments, Inc. | 4.9% | 1,396,279 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| 3.4% | 921,200 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
Holding shares or following this stake? See who's behind INmune Bio Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on INmune Bio Inc. and the records around it.
INmune Bio Inc. elsewhere on the record
Companies that share a holder
- CVI Investments, Inc. also filed stake reports on 48 other companies: Pine Tree Acquisition Corp. (Oct 2026), Sunshine Biopharma Inc. (Oct 2026), Outlook Therapeutics, Inc. (Aug 2026)
- Highbridge Capital Management, LLC also filed stake reports on 83 other companies: Aeon Acquisition I Corp. (Aug 2026), Alpex Acquisition Corp (Aug 2026), Aperture AC (Aug 2026)
Watch INmune Bio Inc.
Get an email when INmune Bio Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on INmune Bio Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on INmune Bio Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on INmune Bio Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Highbridge Capital Management, LLC | 1,454,400 | 0 | 1,454,400 | 0 | SCHEDULE 13G/A, 2025-08-14 |
| CVI Investments, Inc. | 0 | 1,396,279 | 0 | 1,396,279 | SCHEDULE 13G/A, 2025-08-14 |
| Heights Capital Management, Inc. | 0 | 1,396,279 | 0 | 1,396,279 | SCHEDULE 13G/A, 2025-08-14 |
| Praetorian PR LLC | 0 | 771,200 | 0 | 771,200 | SCHEDULE 13G/A, 2025-08-14 |
| Praetorian Capital Fund LLC | 0 | 771,200 | 0 | 771,200 | SCHEDULE 13G/A, 2025-08-14 |
| Praetorian Capital Management LLC | 0 | 771,200 | 0 | 771,200 | SCHEDULE 13G/A, 2025-08-14 |
| Mongolia (Barbados) Corp. | 0 | 150,000 | 0 | 150,000 | SCHEDULE 13G/A, 2025-08-14 |
| Mongolia Growth Group Ltd. | 0 | 150,000 | 0 | 150,000 | SCHEDULE 13G/A, 2025-08-14 |
| Kupperman Harris | 0 | 921,200 | 0 | 921,200 | SCHEDULE 13G/A, 2025-08-14 |
The latest filing names INmune Bio Inc., with its principal executive office as 225 NE MIZNER BLVD, SUITE 640, BOCA RATON, FL 33432 (SCHEDULE 13G/A, 2025-08-14).
What the percentages are based on
The following percentages are based on 26,585,258 Shares outstanding as of June 30, 2025, which is the total number of Shares outstanding as disclosed in the Issuer's Prospectus Supplement on Form 424B5 filed with the Securities and Exchange Commission on June 30, 2025, plus the Shares underlying the Warrants that may be exercised by the Reporting Persons, as applicable.Kupperman Harris, SCHEDULE 13G/A, 2025-08-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-02 | CVI Investments, Inc. | 5.5% | SCHEDULE 13G |
| 2025-08-14 | Highbridge Capital Management, LLC | 5.2% | SCHEDULE 13G/A |
| 2025-08-14 | Kupperman Harris | 3.4% | SCHEDULE 13G/A |
| 2025-08-14 | CVI Investments, Inc. | 4.9% | SCHEDULE 13G/A |
Questions about who owns INmune Bio Inc.
Who owns INmune Bio Inc.?
On this page, one holder's latest ownership filing reports 5% or more of INmune Bio Inc.: Highbridge Capital Management, LLC (5.2%, Schedule 13G/A, filed 2025-08-14).
When did Highbridge Capital Management, LLC buy into INmune Bio Inc.?
The filings give report dates, not purchase dates. The earliest filing from Highbridge Capital Management, LLC on this page is the Schedule 13G/A, filed 2025-08-14, reporting 5.2%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 4 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for INmune Bio Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 14, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for INmune Bio Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.